

United States Patent and Trademark Office

010

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/766,202	01/27/2004	Albert Zorko Abram	021706-002310US	3322
20350 75	90 06/06/2005		EXAM	INER
	AND TOWNSEND AN	LEWIS,	LEWIS, AMY A	
EIGHTH FLOC	CADERO CENTER OR		ART UNIT	PAPER NUMBER
SAN FRANCIS	SAN FRANCISCO, CA 94111-3834			
			DATE MAILED: 06/06/2004	Ē

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/766,202	ABRAM, ALBERT ZORKO	
Office Action Summary	Examiner	Art Unit	
	Amy A. Lewis	1614	
The MAILING DATE of this communication Period for Reply	appears on the cover sheet w	vith the correspondence address	
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication - If the period for reply specified above is less than thirty (30) days, and If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by such any reply received by the Office later than three months after the meanned patent term adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no event, however, may a n. a reply within the statutory minimum of thi priod will apply and will expire SIX (6) MOI tatute, cause the application to become A	reply be timely filed rly (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 2	?7 January 2004.		
2a) ☐ This action is FINAL . 2b) ☑	This action is non-final.		
3) Since this application is in condition for all	owance except for formal mat	ters, prosecution as to the merits is	
closed in accordance with the practice und	ler <i>Ex parte</i> Quayle, 1935 C.[D. 11, 453 O.G. 213.	
Disposition of Claims			
4)⊠ Claim(s) <u>20-55</u> is/are pending in the applic			
4a) Of the above claim(s) is/are with	drawn from consideration.		
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>20-55</u> is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction a	na/or election requirement.		
Application Papers			
9)⊠ The specification is objected to by the Exar	niner.		
10)⊠ The drawing(s) filed on <u>27 January 2004</u> is.	/are: a)⊠ accepted or b)□ o	objected to by the Examiner.	
Applicant may not request that any objection to	the drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the co	· ·	• • • • • • • • • • • • • • • • • • • •	
11) ☐ The oath or declaration is objected to by th	e Examiner. Note the attache	ed Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for for	eign priority under 35 U.S.C.	§ 119(a)-(d) or (f).	
a)⊠ All b)□ Some * c)□ None of: 1.□ Certified copies of the priority docum	ants have been received		
2. Certified copies of the priority docum		Application No. 09/719 662	
		· · · · · · · · · · · · · · · · · · ·	
3. Copies of the certified copies of the	,		
 Copies of the certified copies of the application from the International Bu 	reau (PCT Rule 17.2(a)).		

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

Paper No(s)/Mail Date 3/29/2004.

3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)

Attachment(s)

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.

6) Other: _____.

5) Notice of Informal Patent Application (PTO-152)

Art Unit: 1614

DETAILED ACTION

Page 2

Status of the Case

The remarks and preliminary amendment, filed 27 January 2004, have been entered into the application. Accordingly, the specification has been amended to include continuity data, claims 1-19 are cancelled, and claims 20-55 have been added.

Priority

Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d). The certified copy has been filed in parent Application No. 09/719662, filed on 15 February 2000.

Specification: Abstract

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 20-55 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-40 of U.S. Patent No. 6,730,288 B1 in view of Jones et al. (WO 96/27376).

Instant claims 20-55 are drawn to a topical mousse composition comprising an occlusive agent, an aqueous solvent, and organic cosolvent in an amount to form an occlusive layer on the skin. The mousse composition further comprises a pharmaceutically active ingredient selected from the group consisting of an analgesic, an antifungal, an antibacterial, an anesthetic, an antiviral, an antipruritic, an antihistamine, a xanthine, a sex hormone, an anti-inflammatory, and a corticosteroid. Conflicting claim 1-40 of U.S. Patent No. 6,730,288 B1 is drawn to the same composition with the same pharmaceutical active ingredients, but in the form of an aerosol foam mousse, rather than a topical mousse.

Jones et al. teach that mousse compositions are advantageous for topical administration and are "easier to handle and physically control…allowing proper coverage of the skin site to be treated without premature evaporation of the solvent" (p. 2, paragraph 3; p. 5, paragraph 2).

It would have been obvious to one of ordinary skill in the art to have modified the composition of U.S. Patent No. 6,730,288 B1 to make a topical mousse, motivated by teachings of Jones et al. that the topical composition is easier to administer and provides better skin coverage.

Pertinent Art:

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Art Unit: 1614

- US Pat. 5,833,960
- GB 2 327 344
- US Pat. 5,143,717
- WO 00/15193
- WO 99/04751

The above cited art was not used in any rejections under 35 USC §§ 102 or 103 because they do not recite all required elements of the instant claims nor is there any suggestion to combine the elements in the claimed weight percentages of the claimed composition. (See also the Remarks filed 5 September 2003 in parent Application No. 09/719,662, now US Pat. 6,730,288 B1).

Contact Information:

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy A. Lewis whose telephone number is (571) 272-2765. The examiner can normally be reached on Monday-Friday, 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Chris Low can be reached on (571) 272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Amy A. Lewis Patent Examiner Art Unit 1614

TECHNOLOGY CENTER 1600

Chris Low

SPE

Art Unit 1614